首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   38559篇
  免费   2532篇
  国内免费   1222篇
耳鼻咽喉   65篇
儿科学   1162篇
妇产科学   1289篇
基础医学   2048篇
口腔科学   67篇
临床医学   4483篇
内科学   11143篇
皮肤病学   62篇
神经病学   899篇
特种医学   907篇
外科学   2707篇
综合类   7621篇
现状与发展   5篇
预防医学   2391篇
眼科学   697篇
药学   4983篇
  28篇
中国医学   1555篇
肿瘤学   201篇
  2023年   501篇
  2022年   679篇
  2021年   1267篇
  2020年   1399篇
  2019年   1174篇
  2018年   1263篇
  2017年   1218篇
  2016年   1310篇
  2015年   1290篇
  2014年   2692篇
  2013年   3531篇
  2012年   2116篇
  2011年   2242篇
  2010年   1930篇
  2009年   1744篇
  2008年   1668篇
  2007年   1837篇
  2006年   1672篇
  2005年   1393篇
  2004年   1279篇
  2003年   1148篇
  2002年   956篇
  2001年   927篇
  2000年   777篇
  1999年   646篇
  1998年   548篇
  1997年   593篇
  1996年   493篇
  1995年   536篇
  1994年   447篇
  1993年   311篇
  1992年   327篇
  1991年   269篇
  1990年   236篇
  1989年   202篇
  1988年   211篇
  1987年   178篇
  1986年   162篇
  1985年   208篇
  1984年   191篇
  1983年   91篇
  1982年   122篇
  1981年   120篇
  1980年   127篇
  1979年   62篇
  1978年   44篇
  1977年   49篇
  1976年   41篇
  1975年   19篇
  1973年   18篇
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
2.
3.
《Indian heart journal》2022,74(6):474-477
Background and objectivesAmbulatory blood pressure (BP) monitoring has become useful in the diagnosis and management of hypertensive individuals. In this study we tried to know the role of office and ambulatory BP in treated hypertensive patients.Methods and patientsProspective cohort of 561 treated hypertensive patients were enrolled in the study. Hypertension definitions were according to JNC 8 classification. Office BP and ambulatory BP monitoring was done according to defined protocol.ResultsFrom a subgroup of 158 treated hypertensive patients, 91(16.2%) patients were having white coat hypertension (p value 0.00 by Pearson chi square test). In a subset of 403 patients who were having controlled BP on the day of enrolment as well as on the day of attaching ambulatory BP monitor; 98 (17.4%) patients were having masked uncontrolled hypertension (MUCH). In addition there was very significant percentage of non-dippers and reverse dippers. In our study we found that office BP has a moderate to low specificity and sensitivity and low negative predictive value for overall control in treated hypertensive patients.ConclusionAmbulatory BP monitoring should be included in the management protocol of treated hypertensive patients, for the optimal BP control.  相似文献   
4.
Aims and objectivesVitamin D deficiency is a common finding and there is a suggested association with hypertension. Resistant hypertension is a clinical problem observed in 5–30% of hypertensive patients. Renal denervation (RDN) has been used for patients with resistant hypertension and has proven to lower blood pressure. Our primary goal was to assess the vitamin D serum concentration as a predictor of blood pressure response to RDN in highly selected patients.MethodsThis prospective, nonrandomized, single-center study included 24 patients treated with RDN. Based on their one-year response after RDN, patients were classified as responders or non-responders at six months or at 12 months.ResultsThe median follow-up was 52 months (range, 14-91 months). After RDN, 17 patients (70.8%) had a reduction >5 mmHg in the mean systolic blood pressure, at the first six months of follow-up. At 12 months, 20 patients (83.3%) were responders. Vitamin D levels at baseline (15.1±4.8 vs. 24.2±8.8 ng/ml) and at six months (16.6±7.2 vs. 25±9.2 ng/ml) were lower in early non-responders compared to early responders (p=0.008), without significant variation during follow-up. Even though Vitamin D levels were lower in the total responder's group, no statistically significant differences were found (p=ns).ConclusionIn patients with resistant hypertension, low vitamin D concentrations were associated with an absence of early response to RDN.  相似文献   
5.
6.
7.
BackgroundPre-pregnancy obesity is a well-recognized risk factor for gestational diabetes mellitus (GDM). There is a continuity of obesity from childhood to adolescence and then adulthood. However, it is unknown whether early childhood obesity predicts GDM.MethodsWe investigated the prospective association of childhood triceps skinfold thickness and body mass index (BMI) with GDM risk among women from the Mater-University of Queensland Study of Pregnancy (MUSP), a multigenerational cohort study. A multiple logistic regression model was applied to estimate the odds of experiencing GDM by childhood skinfold thickness and BMI.ResultsOut of 552 women in the study for whom data were available on triceps skinfold thickness and BMI at average age 5 (range 3–7) years old, 52 (9.42%) developed GDM by average age 30 (range 28–33) years. We found that the risk of developing GDM was greater among women who had greater skinfold thickness but not greater BMI at age 5 years. Women who were classified as overweight or obese based on skinfold thickness at age 5 years had an increased odds ratio of GDM compared to women who had normal skinfold thickness. This association remained significant after adjustment for the potential confounders (OR 2.74; 95% confidence interval = 1.28–5.86).ConclusionThe risk of developing GDM was associated with higher skinfold thickness at age 5 years.  相似文献   
8.
背景难治性高血压是一种特殊类型的高血压,病因复杂,治疗难度大,更易引起靶器官损害。近年研究发现,在难治性高血压患者三联常用降压药物治疗基础上添加小剂量螺内酯能有效控制血压。但这些研究规模普遍较小,其有效性与安全性尚需进一步验证。目的系统评价螺内酯治疗难治性高血压的疗效及安全性。方法计算机检索PubMed、Web of Science、The Cochrane Library、中国知网、维普网、万方数据知识服务平台,筛选螺内酯治疗难治性高血压的随机对照研究,检索时间为建库至2021-05-03。由2名研究员独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.3软件进行Meta分析。结果共纳入20项研究。9项研究未报告随机化分组方法,1项研究按纳入顺序编号奇偶分配(错误的随机化方法),7项研究未描述是否采用盲法,4项研究为开放标签,3项研究描述了分配隐藏,1项研究结果数据不完整、未报告对照组治疗后的安全性指标。Meta分析结果显示,疗效方面:与安慰剂和空白对照相比,螺内酯降低诊室血压、24 h动态血压、日间血压及夜间血压的效果好(P<0.05);与其他降压药物总体相比,螺内酯降低诊室收缩压、24 h动态血压、日间收缩压、夜间收缩压及家庭自测收缩压的效果好(P<0.05);与肾脏去交感神经术相比,螺内酯降低日间血压及夜间收缩压的效果好(P<0.05)。安全性方面:与安慰剂相比,应用螺内酯患者的血钾及血肌酐水平高(P<0.05);与其他降压药物总体相比,应用螺内酯患者的血钾水平升高(P<0.05);与肾脏去交感神经术相比,应用螺内酯患者的血肌酐水平升高(P<0.05)。结论螺内酯治疗难治性高血压是相对有效及安全的,但受纳入研究数量和质量的限制,该结论尚需更多高质量研究予以证实。  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号